$6.90
+0.09 (+1.32%)
Open$6.88
Previous Close$6.81
Day High$7.06
Day Low$6.85
52W High$17.44
52W Low$6.41
Volume—
Avg Volume119.3K
Market Cap64.58M
P/E Ratio—
EPS$-19.59
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+110.7% upside
Current
$6.90
$6.90
Target
$14.54
$14.54
$12.76
$14.54 avg
$24.66
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.25M | 5.50M | 4.94M |
| Net Income | 1.19M | 1.50M | 1.15M |
| Profit Margin | 22.6% | 27.2% | 23.3% |
| EBITDA | 2.24M | 2.36M | 2.10M |
| Free Cash Flow | 844.4K | 896.3K | 789.1K |
| Rev Growth | +6.7% | -8.7% | -5.9% |
| Debt/Equity | 0.59 | 0.52 | 0.49 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |